Get the Stockscreener App
20.96
3.51%
0.71
Adaptive Biotechnologies Corp stock is traded at $20.96, with a volume of 6.47M.
It is up +3.51% in the last 24 hours and up +48.34% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
See More
Previous Close:
$20.25
Open:
$20.075
24h Volume:
6.47M
Relative Volume:
2.68
Market Cap:
$3.35B
Revenue:
$295.41M
Net Income/Loss:
$-49.64M
P/E Ratio:
-64.02
EPS:
-0.3274
Net Cash Flow:
$-29.54M
1W Performance:
+19.57%
1M Performance:
+48.34%
6M Performance:
+25.51%
1Y Performance:
+72.37%
1-Day Range:
$19.96
$21.00
1-Week Range:
$17.13
$21.00
52-Week Range:
$9.9551
$21.00
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs TMO, DHR, IDXX, A, NTRA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
20.96 | 3.35B | 295.41M | -49.64M | -29.54M | -0.3274 |
TMO
Thermo Fisher Scientific Inc
|
513.03 | 190.65B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.19 | 138.86B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
551.50 | 43.50B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
136.01 | 38.41B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.91 | 37.51B | 2.50B | -226.32M | 71.51M | -1.6412 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-30-25 | Initiated | Guggenheim | Buy |
| Jun-18-25 | Initiated | Craig Hallum | Buy |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
Adaptive Biotechnologies Corp. Actuals & Estimates (TRADEGATE:1HM) - TradingView
BTIG Maintains a Buy Rating on Adaptive Biotechnologies (ADPT) - Insider Monkey
Adaptive Biotechnologies Corp. Actuals & Estimates (NASDAQ:ADPT) - TradingView
1HM Forecast — Price Target — Prediction for 2027 - TradingView
Adaptive Biotechnologies stock hits 52-week high at 20.82 USD By Investing.com - Investing.com Australia
Form 144 ADAPTIVE BIOTECHNOLOGIES CORPORATION For: 26 June By Investing.com - Investing.com Australia
[144] Adaptive Biotechnologies Corp SEC Filing - Stock Titan
Adaptive Biotechnologies stock hits 52-week high at 20.82 USD - Investing.com
Adaptive Biotechnologies Corp. Actuals & Estimates (FWB:1HM) - TradingView
Adaptive Biotechnologies CorpIssues $345 Million In 0% Convertible Senior Notes Due 2031SEC Filing - TradingView
Form 8K Adaptive Biotechnologies Corp For: 22 June By Investing.com - Investing.com South Africa
Adaptive Biotechnologies Prices $345 Million 0% Convertible Notes Due 2031, Adds Capped Call - TradingView
Adaptive Biotechnologies (Nasdaq: ADPT) sells $345M 0% notes and repays OrbiMed deal - Stock Titan
Adaptive Biotechnologies Corp (ADPT) Institutional Confidence - TradingKey
Insider Sell: Harlan Robins Sells 106,160 Shares of Adaptive Bio - GuruFocus
Adaptive Biotechnologies Corp (ADPT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Adaptive Biotechnologies Corp (ADPT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Adaptive Biotechnologies Corp (ADPT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Adaptive Biotechnologies CSO Harlan Robins sells $1.8m in stock - Investing.com UK
Adaptive Biotechnologies Corp (ADPT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Adaptive Biotechnologies Corp (ADPT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Adaptive Biotechnologies CSO Harlan Robins sells $1.8m in stock By Investing.com - Investing.com India
Adaptive Biotechnologies (ADPT) CSO sells 106K shares under 10b5-1 plan - Stock Titan
ADPT Reiterated by BTIG -- Price Target Maintained at $22 - GuruFocus
Adaptive Biotechnologies Business Separation May Unlock Greater Value - Benzinga
BTIG reiterates Adeptus Biotechnologies stock rating on business split By Investing.com - Investing.com South Africa
Analysts Are Bullish on Top Healthcare Stocks: Pasithea Therapeutics Corp (KTTA), Adaptive Biotechnologies (ADPT) - The Globe and Mail
Adaptive Biotechnologies Corp (ADPT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Adaptive Biotechnologies Corp (ADPT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering - The Manila Times
Adaptive Biotechnologies Announces Pricing of $300 Million Convertible Senior Notes Offering to Enhance Financial Flexibility - Quiver Quantitative
Adaptive Biotechnologies raises $300M zero-interest debt, buys back stock - Stock Titan
Seattle biotech looks to raise up to $288 million amid plans to spin out immune medicine business - The Business Journals
Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses - Benzinga
Stock Market Today: S&P 500, Nasdaq Futures Fall, Dow Gains Amid US-Iran Deal— SpaceX, Dave And Buster's, Western Digital In Focus (UPDATED) - Benzinga
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering - The Manila Times
Adaptive Biotechnologies chief commercial officer sells $95,000 in shares - Investing.com UK
Adaptive Biotechnologies stock falls on convertible debt plan - Investing.com
Adaptive Biotechnologies chief commercial officer sells $95,000 in shares By Investing.com - Investing.com Nigeria
Executive at Adaptive Biotechnologies (ADPT) sells 5,000 shares under 10b5-1 plan - Stock Titan
Adaptive Biotechnologies plans $250M convertible notes offering By Investing.com - Investing.com Australia
Adaptive Biotechnologies plans to separate MRD, Immune Medicine units - Investing.com
Adaptive Biotechnologies plans $250M convertible notes offering - Investing.com
Adaptive Biotechnologies stock falls on convertible debt plan By Investing.com - Investing.com India
Adaptive Biotechnologies proposes $250M convertible notes, plans MRD/Immune Medicine separation - TradingView
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses - The Manila Times
Adaptive Biotechnologies (NASDAQ: ADPT) to sell $250M converts and explore MRD–Immune Medicine split - Stock Titan
Adaptive Biotechnologies plans split: MRD tests vs AI immune unit - Stock Titan
Adaptive Biotechnologies lines up $250M note deal to repay debt, buy back shares - Stock Titan
Kennedy Capital Management LLC Trims Holdings in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Adaptive Bio’s $250M Gambit: A Strategic Split Beyond the Balance Sheet - BriefGlance
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.76%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):